Investor Overview

Investor Presentation
Download Documentation Investor Presentation - March 2017
Get help downloading or viewing the above file types
PTI (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$6.31
Change (%) Stock is Up 0.35 (5.87%)
Volume325,787
Data as of 04/26/17 4:00 p.m. ET
Corporate Profile

Proteostasis Therapeutics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of novel therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. Our initial therapeutic focus is on cystic fibrosis, or CF, which is caused by defects in the cystic fibrosis transmembrane conductance regulator, or CFTR, protein and insufficient CFTR protein function. ... More >>

Recent NewsMore >>
Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
March 30, 2017
Read More


Proteostasis Therapeutics Reports Third Quarter 2016 Financial Results
November 10, 2016
Read More


Proteostasis Therapeutics Announces Conference Call to Provide Clinical and Scientific Update at 30th Annual North American Cystic Fibrosis Conference
October 26, 2016
Read More


Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.
INVESTORS & MEDIA